We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · April 01, 2015

Brentuximab Vedotin as Consolidation Therapy After Autologous Stem-Cell Transplantation in Patients With Hodgkin's Lymphoma

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Brentuximab Vedotin as Consolidation Therapy After Autologous Stem-Cell Transplantation in Patients With Hodgkin's Lymphoma at Risk of Relapse or Progression (AETHERA): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet 2015 Mar 18;[EPub Ahead of Print], CH Moskowitz, A Nademanee, T Masszi, E Agura, J Holowiecki, MH Abidi, AI Chen, P Stiff, AM Gianni, A Carella, D Osmanov, V Bachanova, J Sweetenham, A Sureda, D Huebner, EL Sievers, A Chi, EK Larsen, NN Hunder, J Walewski

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading